Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | PARG | Q86W56 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231530 | 0.94 | SMYD3 (0.57) | SMYD3HTR2CHTR2BPARGPKM | |
| SCHEMBL4231528 | 0.92 | SMYD3 (0.57) | SMYD3HTR2CHTR2BPARGPKM | |
| SCHEMBL4221206 | 0.82 | BRD4 (0.66) | SMYD3PKMIDO1LMNAMAPT | |
| SCHEMBL5843373 | 0.81 | SMYD3 (0.53) | SMYD3PKMIDO1LMNAMAPT | |
| SCHEMBL4896390 | 0.80 | PKM (0.57) | SMYD3HTR2CHTR2BPKMIDO1 | |
| SCHEMBL5843084 | 0.80 | SMYD3 (0.88) | SMYD3PARGPKMIDO1MAPT | |
| SCHEMBL22400694 | 0.79 | TP53 (0.70) | LMNATP53MAPTPOLB | |
| SCHEMBL24152814 | 0.79 | ATM (0.64) | SMYD3PKMIDO1LMNAMAPT | |
| SCHEMBL5840708 | 0.79 | MAOB (0.56) | SMYD3PKMIDO1LMNATP53 | |
| SCHEMBL4907229 | 0.79 | POLB (0.60) | SMYD3PKMIDO1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981880-B2 | 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-19 | — | — | US | disclosed |
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| EP-2016049-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007122219-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATIVES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105216-A1 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS | MKI67, CCNI, CCNA1 | SMYD3 2588/4885HTR2C 441/4885HTR2B 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.